Spreading risk across a broad range of initiatives
Cellgen’s initial market position will be built on a management philosophy that maintains a sharp eye toward the future. In this regard, Cellgen’s future viability is exceptionally robust. Although Cellgen will partner with pharmaceutical partners to bring companion diagnostics to market, we will also develop a broad portfolio of stand-alone diagnostics across a diverse set of major disease indications. These disease areas include oncology, cardiovascular disease, central nervous system, inflammation, infectious disease and autoimmune diseases, but are not limited to.
As the diagram below indicates, the journey from diagnostic inception to actual product launch is both lengthy and uncertain. Before any product can reach the marketplace it must overcome a number of obstacles ranging from initial biomarker discovery, through analytical and clinical validation. There is no guarantee these initiative will achieve marketable status. Nonetheless, Cellgen will partner with strong clinical and research partners to ensure we mitigate as much risk as possible before each assay moves to the validation stages.
Our pipeline reflects our commitment to developing a broad portfolio of assays to help guide treatment decisions